Ocera Therapeutics (OCRX) Misses Q1 EPS by 3c

Ocera Therapeutics (NASDAQ: OCRX) reported Q1 EPS of ($0.36), $0.03 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $33 thousand versus the consensus estimate of $10 thousand.

For earnings history and earnings-related data on Ocera Therapeutics (OCRX) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Ford (F) earnings top estimates in Q1 amid strength in Pro unit; stock up
• ESSA Bancorp (ESSA) Tops Q2 EPS by 13c